eValuation of the Efficacy and toleRability of Vimpat When Added to lEvetiracetam
Public ClinicalTrials.gov record NCT01484977. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Open-label, Single Arm, Study Evaluating Tolerability and Efficacy of Lacosamide When Added to Levetiracetam With Withdrawal of Concomitant Sodium Channel Blocking Antiepileptic Drug in Subjects With Uncontrolled Partial-onset Seizures
Study identification
- NCT ID
- NCT01484977
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- UCB Pharma
- Industry
- Enrollment
- 120 participants
Conditions and interventions
Conditions
Interventions
- Lacosamide Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 30, 2011
- Primary completion
- Nov 30, 2013
- Completion
- Nov 30, 2013
- Last update posted
- Jul 17, 2018
2011 – 2013
United States locations
- U.S. sites
- 30
- U.S. states
- 17
- U.S. cities
- 30
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| 110 | Huntsville | Alabama | — | — |
| 004 | Phoenix | Arizona | — | — |
| 001 | Fresno | California | — | — |
| 008 | Orange | California | — | — |
| 030 | Oxnard | California | — | — |
| 108 | Sacramento | California | — | — |
| 025 | Bradenton | Florida | — | — |
| 015 | Ocala | Florida | — | — |
| 049 | Panama City | Florida | — | — |
| 114 | Port Charlotte | Florida | — | — |
| 012 | Sarasota | Florida | — | — |
| 014 | Tampa | Florida | — | — |
| 003 | Wellington | Florida | — | — |
| 123 | Louisville | Kentucky | — | — |
| 006 | Hammond | Louisiana | — | — |
| 112 | Waldorf | Maryland | — | — |
| 129 | Golden Valley | Minnesota | — | — |
| 023 | Springfield | Missouri | — | — |
| 088 | Missoula | Montana | — | — |
| 020 | Camden | New Jersey | — | — |
| 131 | Greensboro | North Carolina | — | — |
| 002 | Akron | Ohio | — | — |
| 027 | Canton | Ohio | — | — |
| 022 | Columbus | Ohio | — | — |
| 005 | Dayton | Ohio | — | — |
| 013 | Oklahoma City | Oklahoma | — | — |
| 028 | Lubbock | Texas | — | — |
| 017 | Salt Lake City | Utah | — | — |
| 139 | Madison | Wisconsin | — | — |
| 024 | Milwaukee | Wisconsin | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 24 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01484977, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 17, 2018 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01484977 live on ClinicalTrials.gov.